Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson's Disease

Stock Information for Voyager Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Voyager Therapeutics Inc.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.